
“Revolutionizing Breast Cancer Treatment: Genentech’s Itovebi Shows Promising Results for HR-Positive Advanced Breast Cancer Patients”
Exciting News in Cancer Treatment Research Positive Results in Phase III Clinical Trial for INAVO120 Study In a recent announcement, Genentech disclosed positive topline results from the Phase III INAVO120 study, evaluating the efficacy of ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant for individuals with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant, locally advanced or…